Phathom Pharmaceuticals Inc banner

Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 12.64 USD 7.03% Market Closed
Market Cap: $996m

Intrinsic Value

The intrinsic value for Phathom Pharmaceuticals Inc (PHAT) under the Base Case is 34.8 USD. Compared with the current market price of 12.64 USD, the stock appears Undervalued by 64%.

Based on two methods:

Both DCF and multiples point to undervaluation.

PHAT Intrinsic Value
34.8 USD
Undervaluation 64%
Intrinsic Value
Price $12.64
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value $27.84
Get notified when the price drops into your buy zone
Intrinsic Value $34.8
Margin of Safety 20% $27.84
Current Price $12.64
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about PHAT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PHAT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Phathom Pharmaceuticals Inc.

Explain Valuation
Alternatives to PHAT

Wall St
Price Targets

Dividends

Phathom Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Competitive Landscape

Ownership

PHAT Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PHAT stock?

The intrinsic value for Phathom Pharmaceuticals Inc (PHAT) under the Base Case is 34.8 USD.

Is PHAT stock undervalued or overvalued?

Compared with the current market price of 12.64 USD, the stock appears Undervalued by 64%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett